SUBSCRIBE
SUBSCRIBE

TG Therapeutics, Inc.

NEWS
Business
TG Therapeutics to Host Conference Call on Third Quarter 2023 Financial Results and Business UpdateConference call to be held Wednesday, November 1, 2023, at 8:30 AM ET
October 30, 2023
 · 
1 min read
Pharm Country
TG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
October 11, 2023
 · 
13 min read
Drug Development
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
October 2, 2023
 · 
14 min read
Pharm Country
TG Therapeutics to Participate in the 2023 Cantor Global Healthcare ConferenceFireside chat scheduled for Tuesday, September 26, 2023, at 12:25 PM ET
September 22, 2023
 · 
1 min read
Pharm Country
TG Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceFireside chat scheduled for Monday, September 11, 2023, at 10:30 AM ET
September 7, 2023
 · 
1 min read
Business
TG Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
August 1, 2023
 · 
20 min read
Business
TG Therapeutics and Neuraxpharm Announce Ex-US Commercialization Agreement for BRIUMVI® (ublituximab-xiiy)
August 1, 2023
 · 
17 min read
Business
TG Therapeutics to Host Conference Call on Second Quarter 2023 Financial Results and Business Update
July 31, 2023
 · 
1 min read
Pharm Country
TG Therapeutics to Participate in the 2023 Jefferies Healthcare ConferenceFireside chat scheduled for Wednesday, June 7, 2023, at 11:30 AM ET
June 5, 2023
 · 
1 min read
Pharm Country
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting
June 2, 2023
 · 
13 min read
Pharm Country
TG Therapeutics Announces European Commission Approval for BRIUMVI® (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults
June 1, 2023
 · 
13 min read
Drug Development
TG Therapeutics Announces Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting
May 31, 2023
 · 
13 min read
Pharm Country
TG Therapeutics to Participate in the Bank of America Securities 2023 Health Care ConferenceFireside chat scheduled for Tuesday, May 9, 2023, at 3:00 PM PT
May 4, 2023
 · 
1 min read
Business
TG Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
May 1, 2023
 · 
18 min read
Business
TG Therapeutics to Host Conference Call on First Quarter 2023 Financial Results and Business Update
April 28, 2023
 · 
1 min read
Pharm Country
TG Therapeutics Announces Issuance of Permanent J-Code for BRIUMVI® (ublituximab-xiiy) from Centers for Medicare and Medicaid Services
April 27, 2023
 · 
11 min read
Load More
AWARDS
  • 2026 - Best Places to Work - Badge (1).png
JOBS